arrow
A

Antonio Passaro

gustave roussy
H指数:42
被引数:9,160

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

抗体药物偶联物在特定实体瘤中的应用:基于ETOP IBCSG Partners基金会第三次研讨会成果的立场声明更新

2026-07-010
OAAI
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective

肺癌中抗体药物偶联物的生物标志物:病理学家的视角

2026-06-010
PRE
Actionable Gene Alterations in Resected Non-small cell lung cancer: primary results from the AGA-R study

可操作基因改变在切除的非小细胞肺癌中的研究:AGA-R研究的主要结果

2025-10-030
PRE
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

携带EGFR突变型晚期非小细胞肺癌患者使用amivantamab-lazertinib的总体生存率

2025-09-019
PRE
The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation

传统及人工智能基础的临床预测模型在非小细胞肺癌中的研究进展:从模型构建到真实世界验证

2025-08-200
PREAI
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-mutated Non-small Cell Lung Cancer: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study

皮下给药与静脉给药的Amivantamab(联合Lazertinib)在EGFR突变型非小细胞肺癌难治患者中的应用:PALOMA-3研究中的患者满意度与资源利用结果

2025-07-100
OA
ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0)

ESMO临床获益程度量表2.0版(ESMO-MCBS v2.0)

2025-05-220
PRE
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC

Amivantamab联合Lazertinib治疗先前未经治疗的EGFR突变的晚期NSCLC

2024-10-2425
PRE